221121-34-2

Basic information

• Product Name: (2,6-dichlorophenylacetyl)imidazolide
• Synonyms: (2,6-dichlorophenylacetyl)imidazolide
• CAS NO: 221121-34-2
• Molecular Weight: 255.103
• Mol File: 221121-34-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (2,6-dichlorophenylacetyl)imidazolide(CAS DataBase Reference)
• NIST Chemistry Reference: (2,6-dichlorophenylacetyl)imidazolide(221121-34-2)
• EPA Substance Registry System: (2,6-dichlorophenylacetyl)imidazolide(221121-34-2)

Safety Data

• Hazardous Substances Data: 221121-34-2(Hazardous Substances Data)

Upstream product

• 6575-24-2 2-(2,6-dichlorophenyl)acetic acid 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 221121-47-7 ethyl 2-methyl-3-oxo-4-(2,6-dichlorophenyl)butanoate 
• 221121-45-5 ethyl 4-(2,6-dichlorophenyl)-3-oxobutanoate 
• 221121-67-1 5-methyl-2-thioxo-6-(2,6-dichlorobenzyl)-2,3-dihydropyrimidin-4(1H)-one 
• 221121-64-8 6-(2,6-dichlorophenylmethyl)-3,4-dihydro-2-thiopyrimidin-4(3H)-one 

Relevant articles and documents

Development of a scalable synthesis of mevidalen (LY3154207), an orally available positive allosteric modulator of the human dopamine D1 receptor

The evolution from early medicinal chemistry to large-scale production of the chemical synthesis of Lilly D1-positive allosteric modulator (PAM) mevidalen (LY3154207) and its hydroxybenzoate co-crystal is outlined. The issues and steps taken to resolve them are outlined across several generations of synthesis, including unexpected issues that arose during cryogenic addition of MeLi to a key imine intermediate and the use of flow chemistry to enable large-scale production. Ultimately, a process that was used to deliver >100 kg of API to support ongoing clinical trials is described.

Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonylmethylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs

A series of novel 2-(phenylaminocarbonylmethylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones have been designed and synthesized. All of the new compounds were evaluated for their anti-HIV activities in MT-4 cells. Most of these new compounds showed mod

Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity

A simple and efficient methodology for the parallel solution-phase synthesis has been set up to obtain a series of thiouracils, in turn selectively S-benzylated under microwave irradiation to give new S-DABOs. Biological screening led to the identificatio